Under the Securities Exchange Act of 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

The Walden Group, Inc.

15455 Dallas Parkway, Suite 440

Addison, Texas 75001

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box: o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(1)         Based on 37,715,960 shares outstanding as of February 27, 2017, as reported by Daseke, Inc. in its Current Report on Form 8-K filed on February 27, 2017.

2

(1)         Includes (a) 13,757,629 shares held by The Walden Group, Inc. and (b) 28,841 shares held by Mr. Daseke’s spouse.

(2)         Based on 37,715,960 shares outstanding as of February 27, 2017, as reported by Daseke, Inc. in its Current Report on Form 8-K filed on February 27, 2017.

3

Item 1.  Security and Issuer

This Schedule 13D relates to the common stock, $0.0001 par value per share (the “Common Stock”), of Daseke, Inc., a Delaware corporation (the “Company”). The address of the principal executive offices of the Company is 15455 Dallas Parkway, Suite 440, Addison, Texas 75001.

Item 2.  Identity and Background

(a)

1.                The Walden Group, Inc., a Delaware corporation (“The Walden Group”)

2.                Don R. Daseke (together with The Walden Group, the “Filing Parties”)

(b)

1.                The business address of The Walden Group, which also serves as its principal office, is 15455 Dallas Parkway, Suite 440, Addison, Texas 75001.

2.                The principal business address of Mr. Daseke is 15455 Dallas Parkway, Suite 440, Addison, Texas 75001.

(c)

1.                The principal business of The Walden Group is to invest in various companies, including the Company. Mr. Daseke is the President and a director of The Walden Group, which has no other directors or officers or controlling persons.  Mr. Daseke is also the majority stockholder of The Walden Group.

2.                The present principal occupation of Mr. Daseke is Chief Executive Officer, President and Chairman of the Board of Directors of the Company.  The Company’s principal business is providing open deck transportation and logistics solutions and its principal address is 15455 Dallas Parkway, Suite 440, Addison, Texas 7500.

(d)           During the last five years, neither of the Filing Parties has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)           During the last five years, neither of the Filing Parties was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction, as a result of which it or he was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.

(f)           Mr. Daseke is a citizen of the United States of America.

Item 3.  Source and Amount of Funds or Other Consideration

On February 27, 2017, the Company (f/k/a Hennessy Capital Acquisition Corp. II) consummated the previously announced merger of a wholly owned subsidiary of the Company with and into Daseke, Inc., with Daseke, Inc. surviving as a direct wholly owned subsidiary of the Company (the “Business Combination”), in accordance with the Agreement and Plan of Merger, dated December 22, 2016 (the “Merger Agreement”), by and among the Company, HCAC Merger Sub, Inc., Daseke, Inc. and Don R.

4

Daseke, solely in his capacity as the Stockholder Representative (as defined therein).  Subsequent to the closing of the Business Combination, on February 27, 2017, Daseke, Inc. changed its name to “Daseke Companies, Inc.” and the Company changed its name to “Daseke, Inc.”  In this Schedule 13D, references to “Old Daseke” are to Daseke, Inc. prior to the consummation of the Business Combination.

Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each share of Old Daseke common stock issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive approximately 144.204 shares of Common Stock (rounded to the nearest whole share), upon the terms and subject to the conditions set forth in the Merger Agreement. The closing price of the Common Stock was $10.22 per share on the effective date of the Business Combination.

Upon receipt by the transfer agent of requisite documents, The Walden Group will receive  13,757,629 shares of Common Stock, Mr. Daseke will receive 1,308,795 shares of Common Stock and Mr. Daseke’s spouse will receive 28,841 shares of Common Stock, in each case, in exchange for their respective shares of Old Daseke common stock pursuant to the Merger Agreement.

Item 4.  Purpose of Transaction

The information disclosed in Item 3 above is hereby incorporated herein by reference.

The Filing Parties and Mr. Daseke’s spouse acquired the shares of Common Stock reported herein solely for investment purposes. The Filing Parties may from time to time make additional purchases of shares of Common Stock or may dispose of shares of Common Stock reported as beneficially owned in this Schedule 13D, either in the open market, in privately negotiated transactions (which may be with the Company or with third parties) or otherwise, depending on the Company’s business, prospects and financial condition, the market for shares of Common Stock, the ability to dispose of shares pursuant to an effective registration statement under the Securities Act of 1933, as amended, or otherwise in compliance with applicable securities laws, general economic conditions, financial and stock market conditions, other available opportunities, and other future developments.

Mr. Daseke intends to participate in and influence the affairs of the Company through the exercise of his voting rights with respect to the shares of Common Stock for which he has voting power. In addition, Mr. Daseke is the Chief Executive Officer, President and Chairman of the Board of Directors of the Company and, as a result, in the ordinary course or otherwise, may take actions to influence the management, business and affairs of the Company.

Other than as described in this Schedule 13D, neither of the filing Parties have any other present plans or proposals that relate to or would result in any of the matters set forth in Item 4(a)-(j) of Schedule 13D.

5

Item 5.  Interest in Securities of the Issuer

(a)           The Walden Group may be deemed to beneficially own 13,757,629 shares of Common Stock, representing approximately 36.5% of the outstanding shares of Common Stock.  Mr. Daseke may be deemed to beneficially own in the aggregate 15,095,264 shares of Common Stock, representing approximately 40.0% of the outstanding shares of Common Stock.  These percentages are based on the number of shares of Common Stock issued and outstanding immediately following the Business Combination, as reported in the Company’s Current Report on Form 8-K, filed on February 27, 2017.

(b)           The Walden Group has sole voting and sole dispositive power with respect to no shares of Common Stock and shared voting and shared dispositive power over 13,757,629 shares of Common Stock.  Mr. Daseke has sole voting and sole dispositive power over the 1,308,794 shares of Common Stock held directly by him and shared voting and shared dispositive power with respect to 13,786,470 shares of Common Stock, which shares include (i) 13,757,629 shares of Common Stock held directly by The Walden Group and (ii) 28,841 shares of Common Stock held directly by Mr. Daseke’s spouse. Mr. Daseke disclaims beneficial ownership of the shares held of record by The Walden Group or his spouse except to the extent of his pecuniary interest therein.

(c)           The information disclosed in Item 3 above and Item 6 below is hereby incorporated herein by reference.

(d)           Not applicable.

(e)           Not applicable.

Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

The information disclosed in Item 3 above is hereby incorporated herein by reference.

In connection with the Business Combination, the Company entered into an amended and restated registration rights agreement, effective February 27, 2017 (the “Registration Rights Agreement”), with The Walden Group, Mr. Daseke and certain other investors in the Company (each, a “Restricted Stockholder”).   Pursuant to the Registration Rights Agreement, the Company agreed to file, as soon as reasonably practicable (but in any event no later than 45 days after the date on which the Business Combination was consummated), a resale shelf registration statement on Form S-3, for the benefit of the Restricted Stockholders, to register certain securities of the Company, including the shares of Common Stock issued pursuant to the Business Combination.  Also pursuant to the Registration Rights Agreement, certain Restricted Stockholders, including The Walden Group and Mr. Daseke, (each such person, a “Demand Right Holder”) have the right, subject to certain conditions set forth therein, to demand an underwritten offering of their equity securities. The Registration Rights Agreement also grants the Restricted Stockholders, including The Walden Group and Mr. Daseke, certain other customary registration rights, including piggyback rights that allow them to include their Registrable Securities (as defined in the Registration Rights Agreement) in certain underwritten offerings, subject to the limitations set forth therein.  The Company will generally be required to bear the registration expenses, other than underwriting discounts and commissions and transfer taxes, associated with any registration and sale of Registrable Securities held by the Restricted Stockholders. A copy of the Registration Rights Agreement is filed with the Company’s Current Report on Form 8-K, filed on March 3, 2017, as Exhibit 4.1 and is incorporated herein by reference, and the foregoing description of the Registration Rights Agreement is qualified in its entirety by reference thereto.

6

Also in connection with the Business Combination, on February 27, 2017, the Company and Old Daseke’s directors and executive officers, persons that held 1% or more of the shares of Old Daseke common stock immediately prior to the consummation of the Business Combination (which includes The Walden Group and Mr. Daseke) and certain of other Old Daseke stockholders entered into a lock-up agreement with respect to the shares of Common Stock received by such person pursuant to the Business Combination (the “lock-up shares”). Pursuant to the lock-up agreements, each party agreed that for its respective lock-up period (which ranges from 120 days to three years, with The Walden Group and Mr. Daseke’s lock-up period being three years and Mr. Daseke’s spouse’s lock-up period being 180 days), subject to certain exceptions, such party will not (a) sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree to dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, with respect to any lock-up shares of such party, (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any lock-up shares of such party, in cash or otherwise, or (c) publicly announce any intention to effect any transaction specified in clause (a) or (b). Notwithstanding the foregoing, each party may sell or otherwise transfer any lock-up shares of such party to, among other persons, its equity holders or other affiliates or immediate family members, provided in each such case that the transferee thereof agrees to be bound by the restrictions set forth in the lock-up agreement applicable to such lock-up shares.  In addition, The Walden Group and Mr. Daseke may transfer up to 10% of its or his lock-up shares to charities or educational institutions to the extent such transfer does not involve a disposition for value and such transferee agrees to be bound by the terms and conditions of the lock-up agreement until the 180th day after such transferee receives such shares.  A copy of the form of the lock-up agreement is filed with the Company’s Current Report on Form 8-K, filed on December 29, 2016, as Exhibit F to Exhibit 2.1 and is incorporated herein by reference, and the foregoing description of the lock-up agreements are qualified in its entirety by reference thereto.

Effective February 27, 2017, Mr. Daseke entered into a Management Stock Option Award Agreement with the Company, which relate to the 130,000 stock options granted by the Company on February 27, 2017, which vests in five equal annual installments beginning on February 27, 2018 and have an exercise price of $9.98.  A copy of the form of Management Stock Option Award Agreement is filed with the Company’s Current Report on Form 8-K, filed on March 3, 2017, as Exhibit 10.10 and is incorporated herein by reference.

Item 7.  Material to be Filed as Exhibits

1.             Joint Filing Agreement

7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

8

EXHIBIT INDEX

1.             Joint Filing Agreement

9